I wouldn’t be surprised to see offer interest after success of phase 1 human trials. And as I understand, with BDD, they should be able to accelerate and complete phase 1 much sooner. And would expect they start phase 1 within 2-3 months after IDE approval.
No barriers to entry because all the original patents have expired, which in turn greatly limits pricing power and any buyout price. That's the reality.